References
- Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540–53
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317: 703–13
- Matthews DR, Stratton IM, Aldington SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631–40
- Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28–31
- Tugwell P, Ludwin D, Gent M, et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997;24:1122–5
- Duggan DE, Hooke KF, Risley EA, et al. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 1977;201:8–13
- Kador PF, Kinoshita JH, Sharpless NE. The aldose reductase inhibitor site. Metabolism 1986;35:109–13
- Brogden RN, Heel RC, Speight TM, et al. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic disease. Drugs 1978;16:97–114
- Sharma YR Cotlier E. Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: salicylate, indomethacin, oxyphenbutazone, sulindac. Exp Eye Res 1982;35:21–7
- Yamamoto Y, Yin M-J, Lin K-M, et al. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307–14
- Mansour SZ, Hatchell DL, Chandler D, et al. Reduction of basement membrane thickening in diabetic cat retina by sulindac. Invest Ophthalmol Vis Sci 1990;31:457–63
- Gardiner TA, Anderson HR, Degenhardt T, et al. Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 2003;46:1269–75
- Cunha-Vaz JG, Mota CC, Leite EC, et al. Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy. Arch Ophthalmol 1985;103:1307–11
- Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets 2005;6:475–86
- Hamada Y, Araki N, Horiuchi S, et al. Role of polyol pathway in nonenzymatic glycation. Neprol Dial Transplant 1996;11: 95–8
- Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607–14
- Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na+, K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 1995;96: 733–40
- Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450–2
- Bloomgarden ZT. Diabetic retinopathy and neuropathy. Diabetes Care 2005;28:963–70
- Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003;458:283–9
- Wadleigh DJ, Reddy ST, Kopp E, et al. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 2000;275:6259–66
- Kato N, Yashima S, Suzuki T, et al. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 2003;17:374–9
- Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234–44
- Tromp A, Hooymans JM, Barendsen BC, et al. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol 1991;78:153–9